In spite of reduction of rejection rates and improvement in short-term survival post-kidney transplantation, modest progress has occurred in long-term graft attrition over the years. Timely identification of molecular events that precede clinical and histopathological changes might help in early intervention and thereby increase the graft half-life. Evolution of "omics" tools has enabled systemic investigation of the influence of the whole genome, epigenome, transcriptome, proteome and microbiome on transplant function and survival. In this omics era, systemic approaches, in-depth clinical phenotyping and use of strict validation methods are the key for further understanding the complex mechanisms associated with graft function. Systems biology is an interdisciplinary holistic approach that focuses on complex and dynamic interactions within biological systems. The complexity of the human kidney transplant is unlikely to be captured by a reductionist approach. It appears essential to integrate multi-omics data that can elucidate the multidimensional and multilayered regulation of the underlying heterogeneous and complex kidney transplant model. Herein, we discuss studies that focus on genetic biomarkers, emerging technologies and systems biology approaches, which should increase the ability to discover biomarkers, understand mechanisms and stratify patients and responses post-kidney transplantation.
In spite of reduction of rejection rates and improvement in short-term survival post-kidney transplantation, modest progress has occurred in long-term graft attrition over the years. Timely identification of molecular events that precede clinical and histopathological changes might help in early intervention and thereby increase the graft half-life. Evolution of "omics" tools has enabled systemic investigation of the influence of the whole genome, epigenome, transcriptome, proteome and microbiome on transplant function and survival. In this omics era, systemic approaches, in-depth clinical phenotyping and use of strict validation methods are the key for further understanding the complex mechanisms associated with graft function. Systems biology is an interdisciplinary holistic approach that focuses on complex and dynamic interactions within biological systems. The complexity of the human kidney transplant is unlikely to be captured by a reductionist approach. It appears essential to integrate multi-omics data that can elucidate the multidimensional and multilayered regulation of the underlying heterogeneous and complex kidney transplant model. Herein, we discuss studies that focus on genetic biomarkers, emerging technologies and systems biology approaches, which should increase the ability to discover biomarkers, understand mechanisms and stratify patients and responses post-kidney transplantation.
Abbreviations: AR, acute rejection; CKD, chronic kidney disease; DGF, delayed graft function; DSA, donor-specific antigen; ESRD, end-stage renal disease; EWAS, epigenome-wide association study; GWAS, genome-wide association study; I/R, ischemia reperfusion; IF/TA, interstitial fibrosis and tubular atrophy; KT, kidney transplantation; miRNA, microRNA; SNPs, single nucleotide polymorphisms Kidney transplantation (KT) is the treatment of choice for patients with end-stage renal disease (ESRD). Short-term graft survival has significantly improved, but long-term and late failure rates remain a major clinical problem. The national kidney waiting list continues to grow disproportionately to the number of available organ donors (www.optn.org.data).
The improvement in early graft survival is mainly the result of better understanding and addressing acute biological conditions occurring around the transplant time (such as ischemia reperfusion injury [IRI] , immunologic incompatibility or early rejection episodes) (1) . Progressive functional decline, attrition rates and late graft failure are still not well understood, and there are no effective treatments available (2) . The multitude of causes for poorer long-term outcomes include (1) silent events not detectable by standard monitoring tools causing progression to fibrosis, (2) immune and nonimmune mechanisms leading to long-term graft dysfunction, (3) lack of accurate measures or biomarkers to monitor graft function, and (4) ineffective therapies to reverse changes associated with declining graft function or to treat causes of graft failure.
There has been a vast ongoing effort to better understand the different types of injury mechanisms, to find biomarkers for noninvasive monitoring of graft function and to deliver personalized treatment to patients (3) (4) (5) . The current trend has recently shifted from animal models and smallscale, data-driven research to translational research with large-scale, data-generating systemic approaches. A holistic strategy is critical to understand the interplay of the multiple factors that influence the allograft outcome.
A variety of innovative technologies, ranging from genomics, proteomics, peptidomics, antibodyomics, microbiomics and metabolomics-conjunctively referred to as "omics"-have recently entered the medical field. These omics tools have already generated large data set collections and analyses; to further maximize the information integrative methodological approaches that capture the complex biology measured with the individual omics tools are needed. Hence, a systems biology approach, integrating the information provided by omics tools and established diagnostic methods based on in-depth clinical phenotyping, is required. This approach holds the promise to improve understanding of pathogenesis; provide better diagnostic accuracy; and eventually develop effective, highly individualized treatments.
This minireview focuses on studies using omics tools, discovery of biomarkers and systems biology approaches.
Omics Tools in KT
Clinical endpoints are the outcomes that represent the target measures of a study. In KT, graft failure and patient death remain the gold-standard clinical endpoints.
Current short-term endpoints (e.g. acute rejection [AR] , delayed graft function [DGF], occurrence of donorspecific antibodies) have a limited utility in predicting long-term survival (2) . Kidney graft survival is an ideal endpoint but is limited by the need for long-term followup and larger sample sizes. Currently available methods for evaluating kidney graft function are either ineffective, inaccurate (e.g. serum creatinine) or highly invasive, such as tissue biopsies, and are only diagnostic after substantial graft injury has occurred (6) . Clearly, robust surrogate markers need to be identified that are available at an early time point in the transplant course correlating with long-term graft failure. The ideal biomarker would allow Figure 1 : Systems biology approach for biomarker discovery and gaining mechanistic insights. Biomarker discovery when evaluating complex biological conditions (such as progression to chronic renal allograft dysfunction in kidney transplantation) requires a more holistic approach. The rationale of classification and diagnostic prediction using genomic data integrated with clinical phenotype is based on the postulation that complex diseases induce perturbations to molecular interactions and regulations in individuals, resulting in dynamic equilibrium conditions that differ among patients, leading to different outcomes. Individual data sets need to be generated from test and control samples using available omics platforms. The big data generated from each of the functional layers need to be carefully analyzed and processed statistically to discard noise from the "true" signal and to avoid differences related to batch samples, different platforms and sample type (e.g. total peripheral blood vs. peripheral mononuclear cells). Data integration represents the next step on known outcome or unsupervised learning strategies. Softwares such as Ingenuity Pathway Analysis (IPA) and cytoscape can be used to visualize the pathways involved and to deduce the biomarker sets of statistical significance and biological relevance which can be further validated and tested in a clinical setting. The overall approach thus includes a collaborative interdisciplinary team involving physicians, pathologists, scientists and statisticians. Moreover, the results need to be validated in a large and independent set of samples. SNP, single nucleotide polymorphism; miRNA, microRNA.
sensitive and accurate monitoring of graft function; early and specific diagnosis of (immune and nonimmune) injury; evaluation of effective immunosuppression; and assessment of long-term outcome in a noninvasive, costeffective manner. Neither a single biomarker nor panels of markers presenting these characteristics have been implemented in the clinical setting despite great research efforts during recent years.
Consequently, there is a critical need for identifying and evaluating biomarkers that can accurately identify early post-KT those grafts at high risk of progression to chronic allograft dysfunction and graft loss. The application of high-throughput omics techniques, such as genomics (7), proteomics and peptidomics (8) , antibodyomics (9) and metabolomics (10) , has great potential to uncover novel biomarkers in each of these areas. Microbiomics is yet another emerging field reported to mutually interact with and influence each of the aforementioned molecular layers (11) . The current development in the area of molecular biology provides rapid and cost-effective, highthroughput screening at various organization molecular layers with accuracy. Like in other clinical settings, the pursuit of molecular markers through a comprehensive approach is ongoing (Table 1) . In biomarker discovery, oncology is leading the field. However, the discrepancy between a huge number of papers on promising biomarkers, largely based on technologies such as proteomics and DNA microarrays, and the small number of biomarkers validated for routine clinical practice emphasizes the need for systems biology approaches (12) .
Integrative approaches using multi-omics databases in combination with bioinformatics tools and in-depth clinical phenotyping are necessary to understand the different layers of biology that relate to the individual kidney graft outcome. This requires careful design planning. Specifically, banking donor and recipient tissue samples (such as preimplant, protocol and for-cause graft biopsies), perfusates and peripheral blood and urine samples using methods that allow omics evaluation (e.g. use of tubes with inhibitors of RNases) is critical (13) . Additionally, these studies need multidisciplinary team collaborations and accessibility to high-throughput technologies, usually as part of core facilities (14) .
Genomics
The role of genetics in KT is evident from the differences in graft function outcome between ethnic groups. The association of the ApoL1 gene variant in the donor of African descent to graft failure is an example (9, 15) . However, the number of studies evaluating the importance of the influence of the donor genome variation in KT long-term outcomes are limited. More such information on genetic associations of donor genome to transplant outcome will enable better donor-recipient pairing. The International Genetics & Translational Research in Transplantation Network (iGeneTRAiN) Consortium is a collaborative initiative that is working toward this goal (16) .
Hypothesis-driven candidate gene approaches have identified variants of metabolic enzymes and drug transporters in KT recipients, which has enabled physicians to tailor drug doses for individuals carrying these gene variants (17) . Owing to the low penetrance of these gene variants and given the complexity of the traits, an alternative approach toward global genome-wide association studies (GWASs) has just begun in the KT field. The very first study identified associations of two single nucleotide polymorphisms (SNPs) in a T cell receptor alpha gene and a zinc finger protein gene to 5-year creatinine measurements (17) (18) (19) . Another report has been the first to identify the role of copy number variation of the complement factor 4 gene in graft outcome (19) . GWASs have been further explored to study the pathogenesis of ESRD using both binary traits such as the presence of ESRD/chronic kidney disease (CKD)/diabetic nephropathy and continuous traits such as epidermal growth factor receptor (eGFR)/serum creatinine/albuminuria, resulting in a number of loci associated with kidney functioning traits (20) . However, the clinical utility of these traits is still not clear. For instance, many SNPs were found to be associated with CKD, but a scoring system based on these SNPs to predict the incidence of CKD showed a modest power predicting CKD incidence (20, 21) . On the other hand, the most common mechanistically associated genes of growth factors such as TGF-B could not be identified in GWASs due to technical limitations such as the overrepresentation of GWAS probes of the coding regions of the genes and inclusion of only SNPs with a frequency greater than 5% (22) . Therefore, careful consideration of sample size and validation methods is key to deduce meaningful and reproducible data of clinical utility.
Epigenomics
In spite of the presence of exact replicas of genetic information in every human cell, there is variation in spatiotemporal gene expression (23) . It is the dynamic epigenome that modulates the gene expression pattern. The range from single-nucleotide-level modifications (methylation, acetylation, phosphorylation of bases) to high-level chromatin organization (nucleosome positioning, chromatin architecture) constitutes the epigenome and is highly regulated in the cell (23) . DNA methylation is the first and most characterized modification of the chromatin and hence the one with the most developed platforms available to study these modifications. There have been reports on the influence of methylation status of genes, especially of those involved in immune response such as the FOXP3 gene of T regulatory cells or the C3 gene regulatory region in models (clinical and preclinical) of IRI (24, 25) . An epigenome-wide association study (EWAS) on primary kidney myofibroblasts from fibrotic and healthy kidneys identified 12 hypermethylated genes American Journal of Transplantation 2017; 17: 11-21 The microarray data that were used were taken from the gene expression omnibus database. 2 Controls were renal cortex samples from patients with renal carcinoma. 3 mRNA targets of differentially expressed miRNA predicted with online tools. 4 Findings have been reviewed in the review articles provided in the reference list and thus are not directly a part of reference list in this article.
associated with fibroblast activation and transdifferentiated into myofibroblasts. RASAL1 is one of the 12 genes associated with tissue fibrosis beyond the kidney in other tissues such as the liver (22) . An EWAS in a small group of patients showed association of genes, such as NPHP4, QSEC1 and TCF3, to be involved in epithelialmesenchymal transition, with rapid kidney function loss (24, 26) . In addition to DNA methylation changes, histone acetylation and deacetylation have been shown to have an influence on genes such as BMP-7, which help in tissue regeneration after ischemia reperfusion (I/R) injury. Cell culture studies showed antifibrotic and antiinflammatory effects for histone deacetylase inhibitors (24, 27) . Studies in mouse models showed that BMP-7 treatment could reverse renal fibrosis by TET family protein-mediated correction of aberrant methylation of RASAL1. With epigenetics studies, there is scope for developing therapeutic interventions that could directly impact patient care (as epigenetic modifications are dynamic and modifiable), in addition to their use in diagnostics (24) .
With the availability of microarrays for the detection of microRNAs (miRNAs) and the identification of their role in the development and homeostasis of kidneys and in renal pathology (28) , studies were done to identify the role of miRNAs in KT using rodent models, cell culture and patient samples. Many miRNAs were shown to be differentially regulated in I/R models of rodents (21, 29, 30) , few of which were shown to be specific for renal injury by choosing immune-deficient mouse models (30) . MiRNAs in the context of AR were also studied in KT patient biopsy samples, peripheral mononuclear cells and whole blood (29) . Most of the studies had either a small sample size or lacked independent validation (21, 29, 31) . Our group has studied miRNAs in paired urine and biopsy samples of patients with IF/TA against those with normal allografts and has identified 56 differentially expressed miRNAs (32) . The pitfalls and complexity associated with miRNA studies and data interpretation are discussed later in this minireview.
Transcriptomics
The development of high-throughput technologies (e.g. microarrays, RNA sequencing) has enabled extensive study of the dynamic coding and noncoding gene expression repertoire in kidney biopsies, which is now being extended to biological fluids (blood and urine) of patients post-KT (33, 34) . Multiple research groups have reported molecular signatures developed using microarray-based gene expression profiling to identify different clinical categories of rejection and graft dysfunction.
A composite score based on a four-gene signature has been developed to noninvasively determine IF/TA using urine samples in a multicenter study. The same study also discovered and validated a three-gene signature diagnostic and predictive of acute cellular rejection (33, 34 ).
An AR prediction kit using a panel of 17 genes selected from a blood mRNA profile was developed in a multicenter study (35) . The added information of gene expression studies in patients with antibody-mediated rejection (ABMR) to conventional histological assessment has shown improved stratification of patients at high risk for graft loss (36, 37) . While clinical utility of these markers needs to be further determined, early noninvasive prediction and monitoring of graft function are challenging and need to be the focus of KT research.
Proteomics and metabolomics
Proteomics is a technology that can assess the complete set of proteins in a specific matrix: the proteome. As an analogy, metabolomics can assess the complete set of small molecules (defined as <1500 Da; metabolome) in a specific matrix: the metabolome. Initial proteomic studies in AR patients by different groups resulted in discrepancies in findings due to technical, analytical and study design differences (38, 39) . Existing issues in proteomics research include the low dynamic range of the platforms and the lack of understanding of time dependency on underlying mechanistic dynamics during a disease course (40) . Nevertheless, a careful study design in which an integrative analysis combining urine proteomics and gene expression analysis in paired renal transplant biopsies resulted in the identification of differential expressions coordinated at both the mRNA and protein level that could differentiate AR from a normally functioning graft (38, 40) . The dynamic range and flux of the metabolome is much greater when compared to the proteome, owing to its exposure to the environment and microbiome (41) , increasing the challenges associated with the discovery of metabolomic diagnostic markers. However, it is expected that the availability of specific and sensitive molecular markers will impact drug development through the introduction of novel immunosuppressant regimens.
Caveats of one-dimensional approach
The significant cost reduction in high-throughput screening has increased its potential of implementation in clinical practice. However, significant limitations remain to be solved (Table 2) , particularly the reproducibility of findings, standardization of technologies and their integration into clinical context and application. In many studies, the large number of data generated are limited by a small sample size and are often spurious and nonreproducible (42) . The observation that the same gene in a pathway is dysregulated in different ways in different samples in a group (43) implies how crucial data could be lost in noise in a one-dimensional approach. Identified potential biomarkers might fail to qualify for clinical testing due to low diagnostic accuracy and high costs (12, 44) . Given the stratified patient population and heterogeneous tissue environment of the biological sample with multiple functionally interacting loops at various molecular levels, sensitivity and specificity cannot be improved using biomarkers at a single functional level. Regulatory molecules such as miRNAs are dynamic with multiple targets, changing their course depending on the tissue compartment and disease state (45) . Therefore, it is highly probable that multiple markers instead of a single biomarker more accurately represent the responses of the system as a whole.
The Next Step: Moving From a Single Dimension to a Multidimensional Integrative Approach
The biological mechanisms underlying the lack of correlation between rates of AR and long-term graft survival are not fully understood. Specifically, the identification of qualitative differences between acute and chronic rejection processes, the mechanisms that appear to associate with current immunosuppressive agents preferentially blocking the AR process, the relative contribution of immune versus nonimmune responses to chronic graft loss and interindividual differences between upstream regulators of tissue reparation and fibrosis inductors deserve further evaluation.
Conventional approaches to study allograft responses have primarily used reductionist systems to assess the function of a single molecule or a limited subset of molecules. However, the multilayered complexity of renal graft function mandates an integrative approach (Figure 1 ). An important transition from research focused on the functions of single entities (molecules or pathways) to an integrative biology analyzing biological systems as a unified whole is evident. The need for systems biology approaches in medicine is rapidly expanding. Systems biology uses a holistic tactic that considers the entire system as a whole rather than individual components or molecules. Based on such data, novel hypotheses of organ function and failure can be generated and subsequently tested (46) . Data integration involves fitting the individual omic data sets each with their intrinsic variability, noise GWAS, genome-wide association study; miRNA, microRNA; SNP, single nucleotide polymorphism.
and scale. The systems biology approach to reconstruct biological processes aims to combine experimental large data from multi-omics with computational modeling to integrate and elucidate the system as a whole.
Many models of integration are in use depending on the omics selected for integration and their relation with the phenotype. If there is a linear relationship, then a multistage analysis is done (e.g. triangle approach, causal inference). However, KT is a complex trait where the functional outcome is a result of a combination of multiple factors requiring a metadimensional approach for data integration. Fitting models that are based on known outcomes (concatenation-based integration, model-basedintegration, transformation-based-integration) or using unsupervised learning strategies (iClustering, Bayesian approach) have already been applied in other fields such as oncology and could be translated to KT (47, 48) . This integrative strategy has the potential to find biomarkers for conclusive, noninvasive diagnosis and pathological staging that will aid in testing new therapies. Moreover, it can also be adapted for patient stratification, identifying at-risk populations on the basis of disease epidemiology and eventually tailoring treatments to patients via personalized medicine.
This strategy is being successfully implemented in the cancer field. For example, Chari et al (43) used multiple concerted disruption gene analysis in breast cancer to integrate omics data from copy number variation, DNA methylation and gene expression. The data were sequentially analyzed in multiple steps, adding each layer of omics to further refine the data set in order to arrive at a small subset of genes that are affected at the gene expression level through multiple mechanisms. This analysis reduced the sample size needed for the study and helped in the detection of gene disruption with increased frequency in comparison to one-dimensional approaches. Also, the improved accuracy of prognostic biomarkers to determine the aggressiveness of colorectal cancer using an integrated multidimensional analysis compared with the individual components was demonstrated (47) . Moreover, the revolution of integrative omics studies has been also applied in molecular classifications of complex cancers into subtypes and has paved the way for the formation of international consortia such as The Cancer Genome Atlas and International Cancer Genome Consortium, aiming to compile publicly available omics data, which would have a profound impact on translating basic research into precision medicine (46) . A recent report integrated DNA methylation, DNA copy number, gene expression and miRNA expression data from glioma samples and successfully identified three low-grade glioma classes-a long-term pending accomplishment not possible when using histological classifications. Unsupervised clustering of multi-omics data followed by cluster analysis was done to arrive at these distinct molecular subtypes of low-grade gliomas (49) . Attempts at integrating data at two or more functional levels have begun in the transplant field (41, 48, 50, 51) . However, there are many opportunities to improve the approach to address limitations, such as asynchronous experiments, insufficient sample size, batch effects and incomplete data.
Sophisticated computational models and simulations represent integral parts of systems biology (50) . In the kidney transplant field, there is a critical need to understand the complex molecular networks that regulate the interactions among the multiple biological layers involved in the alloimmune response of the host to the graft and the complex response of the graft to the injury. The multifactorial nature of factors affecting long-term outcomes, in addition to the biological processes, environmental conditions and comorbidities, can only be linked using combined and integrative approaches.
Conclusions and Future Directions
In order to better understand the injury mechanisms occurring in KT, integration of molecular measurements of large data sets from different experiments and technologies would be required. Multidimensional integrative approaches including global systems biology assessment are necessary.
Biomarker discovery suffers from difficulties in differentiating techniques noise from real biological mechanisms defined in human samples, intrinsically associated with sample variation, specimen types, techniques and experimental methodology variations-all of which challenge the process of robust biomarker discovery. However, omics data integration using systems biology approaches substantially increases the confidence in the identified biomarkers, as statistical significance from comprehensive data overcomes biological variability. This should result in robust predictive models capable of mapping disease phenotypes, monitoring disease progression, elucidating molecular mechanisms disturbed in the diseased kidney graft and systematic identification of potential therapeutic targets.
One of the major challenges with biomarker discovery and validation in organ transplantation is the complex and multifactorial type of injuries, along with an imperfect "gold standard." Although systems biology approachesspecifically, computationally tractable algorithms capable of generating truly dynamic spatial-temporal modelsare still under development, hypothesis-driven "data mining" of available molecular disease models is crucial for focusing on the specific cellular mechanisms that map back to disease phenotypes and potential therapeutic targets that can be exploited to modify these phenotypes (52, 53) .
Nowadays, reliable techniques currently exist that can support the rigorous integration of large amounts of data while preserving real-world biological complexity, leading to the establishment of a multidimensional integrative landscape (52, 53) . Existing databases such as GEO and tissue banks provide an unlimited amount of data needed for discovery and validation of biomarkers. However, these databases, which are comparable to large registries, often lack robust, complete and sufficiently granular clinical information. In addition, robust outcome markers and large prospective studies, as shown in the oncology field, are key for successful application of the systems biology approach. With this in mind, broad cooperation between physicians, translational researchers, molecular biologists, basic scientists and bioinformatics experts is required to set up the uniform collection and sharing of multiple and complex data from the transplant population.
Until recently, transplant clinical management has had a "one size fits all" design. However, with the development of new technologies and multiple immunosuppressive agents in the pipeline, transplant clinicians have multiple therapeutic options and need to determine the most appropriate course of action for each individual patient. There are many factors that make each patient unique, including genetic polymorphisms, genetic predisposition, different primary disease, environmental effects and interindividual differential responses to the same injury. The long-term goal is to develop individualized, personalized medicine for each transplant patient. An ideal study of transplant biology would combine different omics tools in addition to metadata analyzed by multiple approaches and perhaps machine learning algorithms. With these integrated approaches, we can achieve our goal of personalized medicine.
